PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

251Citations
Citations of this article
475Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Inhibitory properties of PD-1 receptor engagement on activated T cells are well established in physiologic and pathological contexts. In cancer, the use of checkpoint blockade, such as anti-PD-1 antibodies, becomes progressively a reference treatment of a growing number of tumors. Nonetheless, it is also established that PD-1 expression on antigen-specific T cells reflects the functional avidity and anti-tumor reactivity of these T cells. We will discuss this dual significance of PD-1 expression on tumor-specific T cells, due to a complex regulation and the opportunity to exploit this expression to define, monitor and exploit tumor-reactive T cells for immunotherapy purposes.

Cite

CITATION STYLE

APA

Simon, S., & Labarriere, N. (2018, January 2). PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? OncoImmunology. Taylor and Francis Inc. https://doi.org/10.1080/2162402X.2017.1364828

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free